GlaxoSmithKline plans to sell 19 of its consumer-health brands, including the controversial Alli weight-loss drug and Goody's, the headache powder invented in Winston-Salem.

CEO Andrew Witty announced in February that the pharmaceutical giant planned to sell some "non-core" brands to raise money and focus attention on faster-growing products.

Today, the company released a list of products it plans to divest, including Beano gas relief, Debrox ear wax cleanser, Nytol sleep aid and others.

Combined, the products contribute more than $800 million a year in revenue for GSK, the British corporation that has its North American headquarters in Research Triangle Park.